US EditionGlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its stockholders have approved the proposed merger with Crescent Biopharma, Inc., along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics’ special meeting in lieu of the annual meeting of stockholders held on June 5, 2025, including a reverse stock split of GlycoMimetics’ common stock to be effected at the discretion of t…
The president of the Salvador City Council, Carlos Muniz (PSDB), participated today (5) in Brasília in the PSDB National Convention. “A day with many debates about the party. Including the country's political situation and how the party will move forward in the 2026 elections. Brazil increasingly needs dialogue in favor of the quality of life of its population and less polarization. And the PSDB has an important role in the history of the redemo…
Now, to be concrete, we may also need to approve the merger in the convention; if we are created, the new party will meet 7 senators and 28 federal Members.
The Social Democracy Party of Brazil (PSDB) approved this Thursday (5) the merger with the Party during the 17th National Convention of the Sign, held in Brazil (DF). The decision marked a step further for the unifying of the two legends. The merger proposal was approved by the majority. It was: 201 votes in favour 2 against 2 votes in favour to abstain from parliamentary vote, state delegates and members of the national director of the party.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
